Status:
COMPLETED
Pharmacokinetic and Safety Study With Adalimumab in Chinese Subjects With Mild Rheumatoid Arthritis
Lead Sponsor:
AbbVie
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Pharmacokinetic and Safety Study with Adalimumab in Chinese Subjects with Mild Rheumatoid Arthritis
Eligibility Criteria
Inclusion
- Male or Female ages 18 years and older.
- Mild RA.
- Body weight less than 100 kg.
Exclusion
- Wheelchair-bound or bedridden.
- Joint surgery involving joints to be assessed within this study, within two months prior to the Screening visit.
- Intra-articular, intramuscular or intravenous (IV) administration of corticosteroids within 28 days prior to the Screening visit.
- Prior treatment with any TNF antagonist, including adalimumab.
- Positive tuberculin PPD 5.
- Female subjects who are pregnant or breast-feeding.
- History of HIV or of being immuno-compromised.
- History of malignancy.
- Poorly controlled medical condition.
Key Trial Info
Start Date :
June 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00650156
Start Date
June 1 2007
Last Update
November 20 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Site Reference ID/Investigator# 7181
Shanghai, China, 200001